2. Program Goals

3. LDL Established Target for Cardiovascular Risk

4. LDL Lowering

5. PCSK9

6. The Role of PCSK9 in the Regulation of LDL-R Expression

7. PCSK9 Loss-of-function Mutations

9. AEs in A Phase 2 Trial of REGN727/SAR236553

10. Association Between Statin Lipid or Apolipoprotein Levels and Risk of Major Cardiovascular Events

11. Potential Indications for Monoclonal Antibodies to PCSK9

12. PCSK9 Outcome Trials

13. Phase II Trials for Evolocumab

14. OSLER Trial

15. Summary

16. Abbreviations

17. Abbreviations (cont)

18. References

19. References (cont)

20. References (cont)